Tscan Therapeutics, INC

TScan Therapeutics reported Q1 2026 financial results, highlighting progress in its heme and solid tumor programs with key clinical trial milestones expected in Q2 and H2 2026.

TScan Therapeutics announced its Q4 and full-year 2025 financial results, highlighting positive clinical data for its heme program and FDA clearance for new TCR-T candidates.

TScan Therapeutics presented promising clinical data for its TSC-101 therapy in hematologic malignancies and outlined strategic plans for its solid tumor and autoimmunity programs at the J.P. Morgan Healthcare Conference.

TScan Therapeutics' Board of Directors approved a retention program for key executives, including cash and equity awards tied to the advancement of the TSC-101 pivotal trial.

TScan Therapeutics reports Q3 2025 financial results, outlines strategic shift to prioritize heme malignancies, pauses solid tumor enrollment, and extends cash runway into H2 2027.

TScan Therapeutics announced a strategic prioritization of its heme program, a 30% workforce reduction, and an extension of its cash runway into H2 2027, following FDA alignment on its TSC-101 pivotal study design.

TScan Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $28.7 million and continued investment in its TCR-T therapy pipeline.

TScan Therapeutics reports Q3 2025 results, revealing increased losses, a strategic pivot to heme malignancies, and a 30% workforce reduction to extend cash runway into H2 2027.

TScan Therapeutics reported a widened net loss of $71.1 million for the first half of 2025, driven by increased research and development expenses, as it continues to advance its TCR-T cancer therapies.

TScan Therapeutics reports a net loss of $34.1 million for Q1 2025, with collaboration revenue increasing due to the Amgen agreement.

TScan Therapeutics reports a net loss of $29.9 million for the third quarter of 2024, alongside updates on clinical trials and manufacturing.

TScan Therapeutics reports a net loss of $61.8 million for the first half of 2024, while highlighting progress in clinical trials and platform development.

TScan Therapeutics reports increased net losses in 2025, strategically prioritizes its hematologic malignancies program, and pauses solid tumor trial enrollment to focus on in vivo engineering.

Clinical-stage biotechnology company TScan Therapeutics is advancing its T cell receptor (TCR)-engineered T cell therapies for cancer, but continues to incur significant losses and requires additional funding.

TScan Therapeutics has filed an amendment to its 2023 annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

TScan Therapeutics formalizes its employment agreement with CEO Gavin MacBeath and files its annual 10-K report, detailing financial performance and strategic direction.

Baker Bros. Advisors disclosed a grant of 67,000 stock options to TScan Therapeutics director Dr. Stephen R. Biggar.

Director Keith Woods has been granted 67,000 stock options in TScan Therapeutics as part of a standard equity compensation arrangement.

Director Garry A. Nicholson received a grant of 67,000 stock options with a one-year vesting period, aligning board interests with shareholder value.

Director Katina Dorton was granted 67,000 stock options in TScan Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Barbara Klencke was granted 67,000 stock options in TScan Therapeutics, Inc. as part of a standard equity compensation arrangement.

TScan Therapeutics' Chief Financial Officer, Jason Amello, was granted 350,000 stock options with an exercise price of $1.12 per share.

TScan Therapeutics has issued its 2026 proxy statement, seeking shareholder approval for director elections, auditor ratification, and a significant increase in authorized common stock.

TScan Therapeutics will hold its annual stockholder meeting on June 30, 2025, to vote on the election of directors and the ratification of its accounting firm.

TScan Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 30, 2025, to elect directors and ratify the appointment of its independent accounting firm.

TScan Therapeutics has scheduled its 2024 Annual Meeting for June 12, 2024, and is seeking stockholder votes on the election of directors, ratification of the accounting firm, and approval of an amended equity incentive plan.

TScan Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 12, 2024, to vote on the election of directors, ratification of the independent auditor, and approval of an amended equity incentive plan.

Biotechnology Value Fund and affiliates report a 9.99% beneficial ownership stake in TScan Therapeutics, Inc. following recent warrant exercises.

Lynx1 Capital Management LP and Weston Nichols have disclosed a 15.0% beneficial ownership stake in TScan Therapeutics, Inc.'s Voting Common Stock.

Adage Capital Management, L.P. and its principals reported a 2.52% beneficial ownership stake in TScan Therapeutics, Inc., primarily through warrants.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 1.8% beneficial ownership stake in TScan Therapeutics, Inc. as of June 30, 2025.

A group of investment entities associated with Biotechnology Value Fund (BVF), led by Mark N. Lampert, has disclosed a combined 9.99% beneficial ownership stake in TScan Therapeutics, Inc., primarily through common stock and pre-funded warrants.

EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an amended Schedule 13G, disclosing their beneficial ownership of 1.3% of TScan Therapeutics, Inc.'s Voting Common Stock as of March 31, 2025.